PT3393468T - Métodos para tratar imunodeficiências - Google Patents

Métodos para tratar imunodeficiências

Info

Publication number
PT3393468T
PT3393468T PT168801132T PT16880113T PT3393468T PT 3393468 T PT3393468 T PT 3393468T PT 168801132 T PT168801132 T PT 168801132T PT 16880113 T PT16880113 T PT 16880113T PT 3393468 T PT3393468 T PT 3393468T
Authority
PT
Portugal
Prior art keywords
methods
immunodeficiency disease
treating immunodeficiency
treating
disease
Prior art date
Application number
PT168801132T
Other languages
English (en)
Original Assignee
X4 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Inc filed Critical X4 Pharmaceuticals Inc
Publication of PT3393468T publication Critical patent/PT3393468T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT168801132T 2015-12-22 2016-12-22 Métodos para tratar imunodeficiências PT3393468T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562271087P 2015-12-22 2015-12-22
US201662428964P 2016-12-01 2016-12-01

Publications (1)

Publication Number Publication Date
PT3393468T true PT3393468T (pt) 2023-01-19

Family

ID=59091243

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168801132T PT3393468T (pt) 2015-12-22 2016-12-22 Métodos para tratar imunodeficiências

Country Status (12)

Country Link
US (3) US10610527B2 (pt)
EP (1) EP3393468B1 (pt)
JP (2) JP7055380B2 (pt)
CN (1) CN108883091A (pt)
CA (1) CA3009176A1 (pt)
DK (1) DK3393468T3 (pt)
ES (1) ES2935834T3 (pt)
HU (1) HUE060517T2 (pt)
PL (1) PL3393468T3 (pt)
PT (1) PT3393468T (pt)
SI (1) SI3393468T1 (pt)
WO (1) WO2017112894A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス4 ファーマシューティカルズ, インコーポレイテッド がんを処置する方法
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
RU2758473C2 (ru) * 2019-12-31 2021-10-28 Евгений Юрьевич Дашевский Способ выращивания растений методом проточной гидропоники и устройство для его осуществления
EP4117662A4 (en) * 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATMENT OF NEUTROPENIA

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
WO1997009976A2 (en) 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
CA2249401A1 (en) 1996-03-22 1997-09-25 The Dupont Merck Pharmaceutical Company Novel asymmetric synthesis of r-.alpha.-propyl-piperonyl amine and its analogs
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
ES2255733T3 (es) 1997-09-30 2006-07-01 Daiichi Pharmaceutical Co., Ltd. Derivados sulfonilo.
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
KR20010032841A (ko) 1997-12-19 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
ES2265923T3 (es) 1999-03-24 2007-03-01 Anormed Inc. Compuestos heterociclicos que se unen a receptores de quimiocinas.
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
NZ524651A (en) 2000-09-15 2005-08-26 Anormed Inc Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CZ20031910A3 (cs) 2000-12-11 2003-12-17 Tularik Inc. Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
SI1411918T1 (sl) 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN1272322C (zh) 2001-09-12 2006-08-30 阿诺麦德股份有限公司 对映体纯的氨基取代稠合双环的合成
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
DE60325740D1 (de) 2002-08-14 2009-02-26 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US7291631B2 (en) 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
CN101941964A (zh) 2003-04-22 2011-01-12 阿诺麦德股份有限公司 具有促进功效的趋化因子受体结合的杂环化合物
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1730113B1 (en) 2004-03-15 2016-12-28 Genzyme Corporation Process for the synthesis of a cxcr4 antagonist
EP1742936A2 (en) 2004-04-13 2007-01-17 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
WO2006020415A1 (en) 2004-08-02 2006-02-23 Smithkline Beecham Corporation Chemical compounds
KR20070042568A (ko) 2004-08-16 2007-04-23 스미스클라인 비참 코포레이션 화합물
JP2008511669A (ja) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
JP2008514622A (ja) 2004-09-24 2008-05-08 スミスクライン ビーチャム コーポレーション 化合物
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
EP1904645B1 (en) 2005-07-08 2010-08-04 Siemens Healthcare Diagnostics GmbH Method for predicting and monitoring direct response to cancer therapy
JP2009500451A (ja) 2005-07-11 2009-01-08 スミスクライン ビーチャム コーポレーション ピラノピリジン化合物
BRPI0614256B1 (pt) 2005-08-02 2018-10-16 Ineos Europe Ltd processo para a produção de homopolímeros ou copolímeros de dienos conjugados
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
JP5217438B2 (ja) 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
CA2629037A1 (en) 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
PE20070946A1 (es) 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
US20100227880A1 (en) 2006-01-25 2010-09-09 Kristjan Gudmundsson Chemical compounds
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
KR20090013827A (ko) 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008141249A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
WO2009026251A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
JP5690715B2 (ja) 2008-03-28 2015-03-25 アルテイリス・セラピユーテイクス ケモカイン受容体調節因子
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
JP2010016628A (ja) 2008-07-03 2010-01-21 Canon Inc 画像処理装置及び画像処理方法
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
CN102481261B (zh) 2009-09-28 2014-12-31 赞布里国际有限公司 药物组合物
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US20110293521A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012058241A2 (en) 2010-10-26 2012-05-03 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
WO2012075362A2 (en) 2010-12-03 2012-06-07 Emory University Chemokine cxcr4 receptor modulators and used related thereto
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP4215194A1 (en) 2011-01-11 2023-07-26 Dimerix Bioscience Pty Ltd Combination therapy
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20150004239A1 (en) 2012-01-12 2015-01-01 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
AU2013347838A1 (en) 2012-11-26 2015-06-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
WO2014197680A1 (en) 2013-06-05 2014-12-11 Salk Institute For Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
MX2016002185A (es) * 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
EP3044338B1 (en) 2013-09-12 2021-11-24 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ, インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
WO2015143092A1 (en) 2014-03-18 2015-09-24 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
CA2953177C (en) 2014-06-23 2019-07-23 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス4 ファーマシューティカルズ, インコーポレイテッド がんを処置する方法
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
WO2017127811A1 (en) 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
KR102436984B1 (ko) 2016-04-14 2022-08-26 크리에티브이 마이크로테크, 인크. 암 요법을 위한 치료 결정에서 pd-l1 발현을 사용하는 방법
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US20200138804A1 (en) 2017-06-21 2020-05-07 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3080821A1 (en) 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
JP2021506838A (ja) 2017-12-19 2021-02-22 エックス4 ファーマシューティカルズ, インコーポレイテッド 非環式cxcr4阻害剤およびその使用
EP3775877A4 (en) 2018-04-13 2021-12-22 X4 Pharmaceuticals, Inc. CANCER SERUM BIOMARKERS AND METHOD OF USE THEREOF
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Also Published As

Publication number Publication date
US20200268739A1 (en) 2020-08-27
DK3393468T3 (da) 2022-12-19
US10610527B2 (en) 2020-04-07
PL3393468T3 (pl) 2023-01-23
CN108883091A (zh) 2018-11-23
EP3393468A4 (en) 2019-07-31
US20190083485A1 (en) 2019-03-21
WO2017112894A1 (en) 2017-06-29
HUE060517T2 (hu) 2023-03-28
ES2935834T3 (es) 2023-03-10
JP7454255B2 (ja) 2024-03-22
EP3393468A1 (en) 2018-10-31
SI3393468T1 (sl) 2023-01-31
JP2021181501A (ja) 2021-11-25
JP7055380B2 (ja) 2022-04-18
CA3009176A1 (en) 2017-06-29
US20220257586A1 (en) 2022-08-18
EP3393468B1 (en) 2022-09-14
US11219621B2 (en) 2022-01-11
JP2018538337A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
LT3386511T (lt) Hantingtono ligos gydymo būdai
PT3393468T (pt) Métodos para tratar imunodeficiências
HK1244217A1 (zh) 用於治療蛋白質病的方法
GB201500989D0 (en) Process
GB201620049D0 (en) Process
IL278247B (en) mct4 inhibitors to treat the disease
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
GB201505311D0 (en) Process
GB201502893D0 (en) Process
GB201502894D0 (en) Process
HK1248133A1 (zh) 治療神經母細胞瘤的方法
HUE057118T2 (hu) Folyamat
GB201401430D0 (en) Treatment process
GB201501952D0 (en) Process
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
GB201507170D0 (en) Process
GB201501953D0 (en) Process
GB201503635D0 (en) Process
GB201500990D0 (en) Process
GB201504948D0 (en) Process
GB201502814D0 (en) Process
GB201516781D0 (en) Process
GB201501423D0 (en) Process
GB201503607D0 (en) Process
GB201506536D0 (en) Process